# Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT01351623** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 44 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT01351623
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-09
- **Primary completion:** 2016-01-26
- **Final completion:** 2016-01-26
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2017-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01351623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01351623, "Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01351623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*